Augusta-Kranken-Anstalt gGmbH
- Address
- Bergstrasse 26, Grumme, 44791 Bochum, Germany
Augusta-Kranken-Anstalt gGmbH - Comprehensive Oncology Research Center
Augusta-Kranken-Anstalt gGmbH is a distinguished clinical research institution specializing in advanced oncology trials across multiple cancer types. The center demonstrates particular expertise in hematologic malignancies and solid tumor research, conducting sophisticated Phase II and III trials that evaluate novel therapeutic combinations and treatment strategies. Their research portfolio encompasses both curative and palliative approaches, with a strong emphasis on personalized medicine and targeted therapies.
- Acute Myeloid Leukemia (AML) - investigating intensive chemotherapy regimens, CPX-351, and novel combinations with decitabine, venetoclax, and all-trans retinoic acid
- Gastrointestinal Cancers - comprehensive studies in colorectal cancer (preoperative and metastatic settings) and gastric/esophagogastric junction adenocarcinomas
- Thoracic Malignancies - advanced research in non-small cell lung cancer and pleural mesothelioma with immunotherapy combinations
- Lymphomas and Urologic Cancers - trials examining obinutuzumab in marginal zone lymphoma and innovative bladder-sparing approaches in muscle-invasive bladder cancer
The center's research emphasizes cutting-edge immunotherapy combinations, including checkpoint inhibitors such as pembrolizumab, durvalumab, and tremelimumab, often in conjunction with chemotherapy or targeted agents. Their participation in international multicenter trials demonstrates commitment to advancing precision oncology and improving patient outcomes through evidence-based treatment optimization. The institution's diverse trial portfolio reflects a patient-centered approach, addressing both newly diagnosed and treatment-refractory cancers with innovative therapeutic strategies.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 of 3 therapeutic areas and 15 of 41 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 5 by active trials.
lock +4 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +4 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Augusta-Kranken-Anstalt gGmbH
lock Showing 1 of 13 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety of Atezolizumab with FLOT Versus FLOT Alone in Locally Advanced Resectable Esophagogastric Adenocarcinoma | Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH | Phase IV | Not Recruiting | Sep 2018 | — |
IMP list
lock Showing 1 of 41 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 3 | Unknown | 2022-12-01 | 2026-06-16 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.